English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 31 October 2023, 07:00 HKT/SGT
Share:
    

Source: Molekule Consulting
Dr. Daniel Pascheles Rejoins Molekule Consulting as Strategic Advisor

MIAMI, FL, Oct 31, 2023 - (ACN Newswire) - In a significant development that promises to shape the future of Molekule Consulting, we are thrilled to announce the return of Dr. Daniel Pascheles as a Strategic Advisor.

Dr. Pascheles, with an illustrious career spanning over 30 years in the biopharmaceutical competitive and strategic intelligence sector, is poised to bring a wealth of knowledge and expertise to Molekule. His previous roles include leading Competitive Intelligence & Strategy functions at industry leaders Merck & Co./MSD and Aventis, in addition to serving as CEO of Molekule Consulting.

"Dr. Pascheles' return-to-Molekule marks a thrilling, new chapter in our shared story. His homecoming is not just a reunion, but a renewal of our mutual commitment to excellence and innovation. Welcome back, Dr. Pascheles!" expressed David Alderman, President & CEO at Molekule Consulting.

In his pivotal role as Strategic Advisor, Dr. Pascheles will employ his vast industry expertise and strategic prowess to shape and foster Molekule's trajectory of growth and value journey into the future.

"I am thrilled to be back!" remarked Dr. Pascheles. "It is with great excitement that I rejoin the dynamic and growing team at Molekule, and I eagerly anticipate contributing to the company's ongoing success."

For further details on this exciting development, please contact David Alderman at dalderman@molekuleconsulting.com; +1 305.504.3030.

About Molekule Consulting:

Molekule Consulting provides best-in-class strategic intelligence and is solely dedicated to the biopharma sector. We shape the path forward with our strategic intelligence, driving transformative changes across the biopharmaceutical landscape.

Our purpose is clear: to provide high-impact, actionable insights that catalyze growth and foster innovation for biopharmaceutical brands, franchises, and businesses. Our clientele encompasses industry titans, robust mid-sized companies, and ambitious newcomers within the global biopharmaceutical realm.

Interested in learning more about Molekule Consulting's biopharmaceutical-focused strategies and market intelligence? Dive deeper here: www.molekuleconsulting.com

Contact Information

David Alderman, President & CEO, dalderman@molekuleconsulting.com +1 305.504.3030



Topic: Press release summary
Source: Molekule Consulting

Sectors: Daily Finance
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
HKTDC kicks off third International Healthcare Week  
May 16, 2024 18:00 HKT/SGT
CleverTap's 2024 Market Research Report Unveils that Brands Implementing Higher AI Adoption See 4x Boost in Conversions  
May 16, 2024 17:00 HKT/SGT
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers  
May 16, 2024 17:00 HKT/SGT
Q2 Metals Announces Re-Assay Results and Spring 2024 Exploration Plan for Cisco Lithium Property, James Bay Territory, Quebec, Canada  
May 16, 2024 15:09 HKT/SGT
World CX Summit 2024: Steering the future of customer experience forward  
May 16, 2024 15:05 HKT/SGT
Rover Announces and Closes $0.03 Unit Financing  
May 16, 2024 05:00 HKT/SGT
New Research Increases Confidence in the Benefits of Vegan Diets for Dogs  
May 16, 2024 05:00 HKT/SGT
3rd Annual Clean Power & New Energy 2024  
May 15, 2024 21:53 HKT/SGT
Dubai FinTech Summit concludes with over 8,000 visitors from 118 countries  
May 15, 2024 21:40 HKT/SGT
Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles  
Wednesday, May 15, 2024 1:30:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575